J.P. Morgan
J.P. Morgan: Pfizer beats third-quarter expectations, but long-term view still depends on new-drug pipeline
Pfizer raised its 2026 guidance, and JPMorgan modestly increased its forecasts. However, the bank expects revenue and earnings per share to decline over the next two years, with data from most major pipeline programs due at the end of 2027 or later.